| Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison KM Phillips, J Pinilla-Ibarz, E Sotomayor, MR Lee, HSL Jim, BJ Small, ... Supportive Care in Cancer 21, 1097-1103, 2013 | 141 | 2013 |
| A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML) E Padron, A Dezern, M Andrade-Campos, K Vaddi, P Scherle, Q Zhang, ... Clinical Cancer Research 22 (15), 3746-3754, 2016 | 109 | 2016 |
| Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS) GA Abel, F Efficace, RJ Buckstein, S Tinsley, JG Jurcic, Y Martins, ... Haematologica 101 (6), 781, 2016 | 81 | 2016 |
| A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes RS Komrokji, S Wei, AW Mailloux, L Zhang, E Padron, D Sallman, ... Clinical Lymphoma Myeloma and Leukemia 19 (3), 157-161, 2019 | 43* | 2019 |
| Practical management of lenalidomide-related rash SM Tinsley, SE Kurtin, JA Ridgeway Clinical Lymphoma Myeloma and Leukemia 15, S64-S69, 2015 | 43 | 2015 |
| Mindfulness-based stress reduction for breast cancer survivors (MBSR (BC)): evaluating mediators of psychological and physical outcomes in a large randomized controlled trial CA Lengacher, LF Gruss, KE Kip, RR Reich, KG Chauca, MS Moscoso, ... Journal of behavioral medicine 44 (5), 591-604, 2021 | 34 | 2021 |
| Treatment choices: a quality of life comparison in acute myeloid leukemia and high-risk myelodysplastic syndrome SM Tinsley, SK Sutton, R Thapa, J Lancet, SC McMillan Clinical Lymphoma Myeloma and Leukemia 17, S75-S79, 2017 | 25 | 2017 |
| Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes LE Aguirre, N Al Ali, DA Sallman, S Ball, AG Jain, O Chan, ... Leukemia 37 (7), 1530-1539, 2023 | 22 | 2023 |
| Management of transfusion-related iron overload in patients with myelodysplastic syndromes J Shah Number 3/June 2012 16 (3), 37-46, 2012 | 21 | 2012 |
| Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology SM Tinsley, C Grande, K Olson, L Plato, I Jacob Journal of the Advanced Practitioner in Oncology 9 (7), 699-716, 2018 | 20 | 2018 |
| Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes RS Komrokji, E Padron, D Yu, WJ Fulp, Y Rodriguez, S Tinsley, AF List, ... American journal of hematology 89 (8), 809-812, 2014 | 19 | 2014 |
| Safety profiles of second‐line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia SM Tinsley Journal of clinical nursing 19 (9‐10), 1207-1218, 2010 | 18 | 2010 |
| Triple-negative myelofibrosis: disease features, response to treatment and outcomes LEE Aguirre, AG Jain, S Ball, N Al Ali, SM Tinsley-Vance, DA Sallman, ... Blood 138, 1494, 2021 | 10 | 2021 |
| Practical guide to bone marrow sampling for suspected myelodysplastic syndromes JA Ridgeway, S Tinsley, SE Kurtin Journal of the Advanced Practitioner in Oncology 8 (1), 29, 2017 | 10 | 2017 |
| A product of clash of titans or true reflection of disease biology? Validation of 2022 WHO and ICC classifications in a large dataset of patients with Myelodysplastic syndrome S Ball, AM Singh, NA Ali, LE Aguirre, AG Jain, ZI Schwabkey, ... Blood 140 (Supplement 1), 1118-1120, 2022 | 9 | 2022 |
| Transitioning patients with iron overload from Exjade to Jadenu SM Tinsley, CM Hoehner-Cooper Journal of Infusion Nursing 41 (3), 171-175, 2018 | 9 | 2018 |
| Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis. M Veliz, R Santana, JE Lancet, RS Komrokji, MA Kharfan-Dabaja, ... Blood 114 (22), 2376, 2009 | 9 | 2009 |
| Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy L Nodzon, A Fadol, SM Tinsley Journal of Advanced Practitioner in Oncology 13 (2), 127-142, 2022 | 7 | 2022 |
| Lenalidomide and prednisone in low and intermediate-1 IPSS risk, non-Del (5q) patients with myelodysplastic syndromes: Phase 2 clinical trial RS Komrokji, NH Al Ali, E Padron, C Cogle, S Tinsley, D Sallman, ... Clinical Lymphoma Myeloma and Leukemia 19 (4), 251-254, 2019 | 7 | 2019 |
| An integrative review of sex differences in quality of life and symptoms among survivors of hematologic malignancies SM Tinsley-Vance, DSD Mertilus, L Nodzon, CA Lengacher Oncology nursing forum 50 (3), 299, 2023 | 6 | 2023 |
Rami KomrokjiH Lee Moffitt Cancer CenterEmail yang diverifikasi di moffitt.org
